Insider Buying: Orthocell Limited (ASX:OCC) Insider Acquires 35,000 Shares of Stock

Orthocell Limited (ASX:OCC) insider John Wielen bought 35,000 shares of the company’s stock in a transaction on Monday, April 15th. The shares were bought at an average price of A$0.39 ($0.25) per share, for a total transaction of A$13,650.00 ($8,806.45).

Orthocell Price Performance

The company has a current ratio of 4.60, a quick ratio of 5.07 and a debt-to-equity ratio of 34.88.

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries.